Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas B Muchmore

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Diabetes/Metabolism Research and Reviews|January 6, 2017
Hypoglycemia evaluation and reporting in diabetes: Importance for the development of new therapiesDavid C Klonoff, G Alexander Fleming, Douglas B Muchmore, et al.
Vascular Health and Risk Management|January 19, 2008
Inhaled insulin for controlling blood glucose in patients with diabetesBernard L Silverman, Christopher J Barnes, Barbara N Campaigne, et al.
Diabetes Technology & Therapeutics|December 6, 2011
Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidaseMarcus Hompesch, Douglas B Muchmore, Linda Morrow, et al.
Diabetes Care|October 9, 2012
Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidaseLinda Morrow, Douglas B Muchmore, Marcus Hompesch, et al.
Diabetes Technology & Therapeutics|July 1, 2011
Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteersLinda Morrow, Douglas B Muchmore, Elizabeth A Ludington, et al.
Diabetes Care|September 26, 2019
Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A 6-Month Phase 2b Study in Type 1 DiabetesDavid Klonoff, Bruce Bode, Nathan Cohen, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 12, 2003
Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal womenRobert S Weinstein, A Michael Parfitt, Robert Marcus, et al.
Diabetes Technology & Therapeutics|September 24, 2009
AIR insulin capsules of different dose strengths may be combined to yield equivalent pharmacokinetics and glucodynamicsAmparo de la Peña, Mary Seger, Klaus Rave, et al.
Diabetes Technology & Therapeutics|September 24, 2009
Does availability of AIR insulin increase insulin use and improve glycemic control in patients with type 2 diabetes?Richard M Bergenstal, Nick Freemantle, Malgorzata Leyk, et al.
Diabetes Technology & Therapeutics|September 24, 2009
Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargineJulio Rosenstock, Freddy G Eliaschewitz, Cory R Heilmann, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Diabetes/Metabolism Research and Reviews|January 6, 2017
Hypoglycemia evaluation and reporting in diabetes: Importance for the development of new therapiesDavid C Klonoff, G Alexander Fleming, Douglas B Muchmore, et al.
Vascular Health and Risk Management|January 19, 2008
Inhaled insulin for controlling blood glucose in patients with diabetesBernard L Silverman, Christopher J Barnes, Barbara N Campaigne, et al.
Diabetes Technology & Therapeutics|December 6, 2011
Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidaseMarcus Hompesch, Douglas B Muchmore, Linda Morrow, et al.
Diabetes Care|October 9, 2012
Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidaseLinda Morrow, Douglas B Muchmore, Marcus Hompesch, et al.
Diabetes Technology & Therapeutics|July 1, 2011
Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteersLinda Morrow, Douglas B Muchmore, Elizabeth A Ludington, et al.
Diabetes Care|September 26, 2019
Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A 6-Month Phase 2b Study in Type 1 DiabetesDavid Klonoff, Bruce Bode, Nathan Cohen, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 12, 2003
Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal womenRobert S Weinstein, A Michael Parfitt, Robert Marcus, et al.
Diabetes Technology & Therapeutics|September 24, 2009
AIR insulin capsules of different dose strengths may be combined to yield equivalent pharmacokinetics and glucodynamicsAmparo de la Peña, Mary Seger, Klaus Rave, et al.
Diabetes Technology & Therapeutics|September 24, 2009
Does availability of AIR insulin increase insulin use and improve glycemic control in patients with type 2 diabetes?Richard M Bergenstal, Nick Freemantle, Malgorzata Leyk, et al.
Diabetes Technology & Therapeutics|September 24, 2009
Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargineJulio Rosenstock, Freddy G Eliaschewitz, Cory R Heilmann, et al.
Pageof 4